MaxCyte Regulatory News (MXCT)

MaxCyte, Inc.

("MaxCyte" or the "Company")

Total Voting Rights

Gaithersburg, Maryland - 2 June 2021: MaxCyte (LSE: MXCT, MXCN), the global cell-based medicines and life sciences company, announces that pursuant to its block admission facility, details of which were announced on 2 May 2017, it has recently issued 34,722 shares of common stock, $0.01 par, of the Company ("Common Stock") in satisfaction of the exercise of share options.

The new Common Stock will rank pari passu with the existing shares of common stock of the Company. The total issued stock capital of the Company following the recent issue of the new Common Stock is 84,719,345 shares of Common Stock. Shareholders in the Company may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the stock capital of the Company.

The number of unrestricted shares of Common Stock trading under the symbol 'MXCT' is 84,389,345 and the number of restricted shares of Common Stock trading under the symbol 'MXCN' will be 330,000.  

For further information, please contact:

About MaxCyte

MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. MaxCyte's existing customer base ranges from large biopharmaceutical companies, including all of the top 10, and 20 of the top 25, pharmaceutical companies based on 2020 global revenue, to hundreds of biotechnology companies and academic centers focused on translational research. MaxCyte has granted 13 strategic platform licences to commercial cell therapy developers. Including these strategic platform licences, MaxCyte has granted research and clinical licences with academic and industry customers covering over an estimated 140 programs, and clinical licences with academic and industry customers covering over an estimated 100 programs being developed for use in humans. MaxCyte was founded in 1998 and is headquartered in Gaithersburg, Maryland, US. For more information, visit www.maxcyte.com.